Greenovation Biotech GmbH

2018-08-21T13:30:13+00:00

L-EigenkapitalAgentur (Karlsruhe)

Other investors:

Günter Steffen

ZFHN Partner:

2006

Initial investment:

Greenovation supplies highly efficient glycoproteins for the targeted treatment of rare diseases.

Dr. Thomas Frischmuth

Chief Executive

L-EigenkapitalAgentur (Karlsruhe)

Other investors:

Günter Steffen

ZFHN Partner:

2006

Initial investment:

Greenovation supplies highly efficient glycoproteins for the targeted treatment of rare diseases.

Dr. Thomas Frischmuth

Chief Executive

Greenovation is a biopharmaceuticals company.

As a CDMO (a contract development and manufacturing organization), Greenovation provides its customers with its own production technology for the development and production of protein-based pharmaceuticals. This so-called BryoTechnology utilizes the unique advantages of the physcomitrella patens moss, and makes possible the production of a broad range of complex biopharmaceuticals.

Using its own clinical development program, Greenovation exploits the advantages of this BryoTechnology to produce highly effective glycoproteins for the treatment of orphan diseases. The lead product is alpha-galactosidase, used to treat Fabry disease.

The financial and consultative support from ZFHN has enabled us to develop Greenovation's technology to the point of market readiness. ZFHN has an extensive network through which we were able to make valuable contacts.

Dr. Thomas Frischmuth

CEO

The financial and consultative support from ZFHN has enabled us to develop Greenovation's technology to the point of market readiness. ZFHN has an extensive network through which we were able to make valuable contacts.

Dr. Thomas Frischmuth

CEO

1999
Founding of Greenovation Pflanzenbiotechnologie, by Prof. Dr. Gunther Neuhaus and Prof. Dr. Ralf Reski (both of the Albert Ludwigs University in Freiburg)
2006
ZFHN invests in Greenovation. Following investments by LEA Eigenkapital AG and other parties in Greenovation in 2002, from this point on, ZFHN is responsible for the financing and the further development of the company.
2014
First-ever production of a GMP-compliant drug substance manufactured in moss for clinical use.
2015
The German Federal Institute for Drugs and Devices gives its approval to Greenovation to begin a phase-I clinical trial in Europe for moss-aGal (agalsidase), the first-ever drug produced in moss worldwide.
2017
Greenovation Biotech GmbH successfully completes the clinical stage-I study of mossaGal for the treatment of Fabry disease.